{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:43:45Z","timestamp":1792673025939,"version":"4.5.0"},"reference-count":78,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T00:00:00Z","timestamp":1608768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Myelin oligodendrocyte glycoprotein (MOG)-associated disease (MOGAD) is a rare, antibody-mediated inflammatory demyelinating disorder of the central nervous system (CNS) with various phenotypes starting from optic neuritis, via transverse myelitis to acute demyelinating encephalomyelitis (ADEM) and cortical encephalitis. Even though sometimes the clinical picture of this condition is similar to the presentation of neuromyelitis optica spectrum disorder (NMOSD), most experts consider MOGAD as a distinct entity with different immune system pathology. MOG is a molecule detected on the outer membrane of myelin sheaths and expressed primarily within the brain, spinal cord and also the optic nerves. Its function is not fully understood but this glycoprotein may act as a cell surface receptor or cell adhesion molecule. The specific outmost location of myelin makes it a potential target for autoimmune antibodies and cell-mediated responses in demyelinating processes. Optic neuritis seems to be the most frequent presenting phenotype in adults and ADEM in children. In adults, the disease course is multiphasic and subsequent relapses increase disability. In children ADEM usually presents as a one-time incident. Luckily, acute immunotherapy is very effective and severe disability (ambulatory and visual) is less frequent than in NMOSD. A critical element of reliable diagnosis is detection of pathogenic serum antibodies MOG with accurate, specific and sensitive methods, preferably with optimized cell-based assay (CBA). MRI imaging can also help in differentiating MOGAD from other neuro-inflammatory disorders. Reports on randomised control trials are limited, but observational open-label experience suggests a role for high-dose steroids and plasma exchange in the treatment of acute attacks, and for immunosuppressive therapies, such as steroids, oral immunosuppressants and rituximab as maintenance treatment. In this review, we present up-to-date clinical, immunological, radiographic, histopathological data concerning MOGAD and summarize the practical aspects of diagnosing and managing patients with this disease.<\/jats:p>","DOI":"10.3390\/ijms22010100","type":"journal-article","created":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T09:02:44Z","timestamp":1608800564000},"page":"100","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":157,"title":["Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management"],"prefix":"10.3390","volume":"22","author":[{"given":"Wojciech","family":"Ambrosius","sequence":"first","affiliation":[{"name":"Department of Neurology, Poznan University of Medical Sciences, 49 Przybyszewskiego Street, 60-355 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u0142awomir","family":"Michalak","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Neurochemistry and Neuropathology, Poznan University of Medical Sciences, 49 Przybyszewskiego Street, 60-355 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Kozubski","sequence":"additional","affiliation":[{"name":"Department of Neurology, Poznan University of Medical Sciences, 49 Przybyszewskiego Street, 60-355 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0618-1637","authenticated-orcid":false,"given":"Alicja","family":"Kalinowska","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Neurochemistry and Neuropathology, Poznan University of Medical Sciences, 49 Przybyszewskiego Street, 60-355 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1749-6632.1965.tb20235.x","article-title":"Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis","volume":"122","author":"Schumacher","year":"1965","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: Guidelines for research protocols","volume":"1393","author":"Poser","year":"1983","journal-title":"Ann. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis opstica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Jasiak-Zatonska, M., Kalinowska-Lyszczarz, A., Michalak, S., and Kozubski, W. (2016). The immunology of neuromyelitis optica\u2014Current knowledge, clinical implications, controversies and future perspectives. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17030273"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG Encephalomyelitis: International Recommendations on Diagnosis and Antibody Testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J. Neuroinflamm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/PL00012510","article-title":"Myelin Sheaths: Glycoproteins Involved in Their Formation, Maintenance and Degeneration","volume":"59","author":"Quarles","year":"2002","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.4049\/jimmunol.116.5.1439","article-title":"Studies on Autoimmune Encephalomyelitis in the Guinea Pig. II. An in Vitro Investigation on the Nature, Properties, and Specificity of the Serum Demyelinating Factor","volume":"116","author":"Lebar","year":"1976","journal-title":"J. Immunol."},{"key":"ref_10","first-page":"1851","article-title":"A Novel Myelin-Associated Glycoprotein Defined by a Mouse Monoclonal Antibody","volume":"59","author":"Linnington","year":"1984","journal-title":"J. Neuroimmunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0896-8411(89)90149-2","article-title":"Chronic Experimental Autoimmune Encephalomyelitis in the Guinea Pig. Presence of Anti-M2 Antibodies in Central Nervous System Tissue and the Possible Role of M2 Autoantigen in the Induction of the Disease","volume":"2","author":"Lebar","year":"1989","journal-title":"J. Autoimmun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1046\/j.1471-4159.1995.65010309.x","article-title":"Characterization of CDNA and Genomic Clones Encoding Human Myelin Oligodendrocyte Glycoprotein","volume":"65","author":"Hilton","year":"1995","journal-title":"J. Neurochem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1046\/j.1471-4159.1996.67052219.x","article-title":"Investigation of Myelin\/Oligodendrocyte Glycoprotein Membrane Topology","volume":"67","author":"Kroepfl","year":"2002","journal-title":"J. Neurochem."},{"key":"ref_14","first-page":"2219","article-title":"Concepts of Myelin and Myelination in Neuroradiology","volume":"67","author":"Barkovich","year":"2000","journal-title":"Am. J. Neuroradiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/B978-0-444-56378-1.00073-3","article-title":"Myelin Oligodendrocyte Glycoprotein (MOG): An Archetypal Target for Demyelinating Autoantibodies in the Central Nervous System","volume":"73","author":"Linington","year":"2014","journal-title":"Autoantibodies"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/978-1-4939-1154-7_11","article-title":"Role of Myelin-Associated Glycoprotein (Siglec-4a) in the Nervous System","volume":"9","author":"Lopez","year":"2014","journal-title":"Adv. Neurobiol."},{"key":"ref_17","first-page":"2219","article-title":"Myelin Oligodendrocyte Glycoprotein Is Expressed in the Peripheral Nervous System of Rodents and Primates","volume":"67","author":"Pagany","year":"2003","journal-title":"Neurosci. Lett."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e503","DOI":"10.1212\/NXI.0000000000000503","article-title":"MOG Antibodies in Combined Central and Peripheral Demyelination Syndromes","volume":"5","author":"Stephens","year":"2018","journal-title":"Neurol. Neuroimmunol. NeuroInflamm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8094","DOI":"10.1021\/bi901005f","article-title":"Structural Polymorphism and Multifunctionality of Myelin Basic Protein","volume":"48","author":"Harauz","year":"2009","journal-title":"Biochemistry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1471-4159.1997.69010214.x","article-title":"Demyelinating Antibodies to Myelin Oligodendrocyte Glycoprotein and Galactocerebroside Induce Degradation of Myelin Basic Protein in Isolated Human Myelin","volume":"69","author":"Menon","year":"2002","journal-title":"J. Neurochem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1212\/NXI.0000000000000012","article-title":"Antibodies to MOG Have a Demyelination Phenotype and Affect Oligodendrocyte Cytoskeleton","volume":"1","author":"Dale","year":"2014","journal-title":"Neurol. Neuroimmunol. NeuroInflamm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.bbagen.2017.06.025","article-title":"The Role of Human Natural Killer-1 (HNK-1) Carbohydrate in Neuronal Plasticity and Disease","volume":"1861","author":"Morise","year":"2017","journal-title":"Biochim. et Biophys. Acta Gen. Subj."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1111\/j.1471-4159.1993.tb09822.x","article-title":"Human Myelin\/Oligodendrocyte Glycoprotein: A New Member of the L2\/HNK-1 Family","volume":"61","author":"Burger","year":"1993","journal-title":"J. Neurochem."},{"key":"ref_24","first-page":"2455","article-title":"The B7-CD28 Superfamily","volume":"1861","author":"Sharpe","year":"2002","journal-title":"Nature Reviews Immunology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.4049\/jimmunol.178.5.3323","article-title":"C3d Binding to the Myelin Oligodendrocyte Glycoprotein Results in an Exacerbated Experimental Autoimmune Encephalomyelitis","volume":"178","author":"Chan","year":"2007","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1172\/JCI3022","article-title":"MHC haplotype-dependent regulation of MOG-induced EAE in rats","volume":"102","author":"Weissert","year":"1998","journal-title":"J. Clin. Invest."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/brain\/awl075","article-title":"Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research","volume":"129","author":"Gold","year":"2006","journal-title":"Brain"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1084\/jem.20021603","article-title":"Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis","volume":"197","author":"Bettelli","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1177\/1352458515622986","article-title":"Screening for MOG-IgG and 27 Other Anti-Glial and Anti-Neuronal Autoantibodies in \u201cpattern II Multiple Sclerosis\u201d and Brain Biopsy Findings in a MOG-IgG-Positive Case","volume":"22","author":"Jarius","year":"2016","journal-title":"Mult. Scler."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/brain\/122.11.2047","article-title":"Antibodies against the Myelin Oligodendrocyte Glycoprotein and the Myelin Basic Protein in Multiple Sclerosis and Other Neurological Diseases: A Comparative Study","volume":"122","author":"Reindl","year":"1999","journal-title":"Brain"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/135245850100700503","article-title":"Anti-MOG and Anti MBP Antibody Subclasses in Multiple Sclerosis","volume":"7","author":"Egg","year":"2001","journal-title":"Mult. Scler. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJMoa022328","article-title":"Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis after a First Demyelinating Event","volume":"349","author":"Berger","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1212\/01.WNL.0000127615.15768.AE","article-title":"Similar Low Frequency of Anti-MOG IgG and IgM in MS Patients and Healthy Subjects","volume":"62","author":"Lampasona","year":"2004","journal-title":"Neurology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1056\/NEJMoa063602","article-title":"Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis","volume":"356","author":"Kuhle","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_35","first-page":"1","article-title":"Frequency of Myelin Oligodendrocyte Glycoprotein Antibody in Multiple Sclerosis: A Multicenter Cross-Sectional Study","volume":"7","author":"Ruiz","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease: An Immunopathological Study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"17206","DOI":"10.1074\/jbc.M111.304246","article-title":"Autoantigen conformation influences both B- and T-cell responses and encephalitogenicity","volume":"287","author":"Albert","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e1250","DOI":"10.1212\/WNL.0000000000007096","article-title":"A Multicenter Comparison of MOG-IgG Cell-Based Assays","volume":"92","author":"Waters","year":"2019","journal-title":"Neurology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-Antigen Tetramers Discriminate between Myelin Autoantibodies to Native or Denatured Protein","volume":"13","author":"McLaughlin","year":"2007","journal-title":"Nat. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1212\/NXI.0000000000000674","article-title":"International Multicenter Examination of MOG Antibody Assays","volume":"7","author":"Reindl","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG Serostatus with Relapse after Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders","volume":"75","author":"Majed","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/ana.21916","article-title":"Antibodies to Native Myelin Oligodendrocyte Glycoprotein in Children with Inflammatory Demyelinating Central Nervous System Disease","volume":"66","author":"Brilot","year":"2009","journal-title":"Ann. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1177\/1352458514566666","article-title":"Anti-MOG Antibodies Plead against MS Diagnosis in an Acquired Demyelinating Syndromes Cohort","volume":"21","author":"Ketelslegers","year":"2015","journal-title":"Mult. Scler."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00415-017-8583-z","article-title":"MOG Antibody-Related Disorders: Common Features and Uncommon Presentations","volume":"264","author":"Ruiz","year":"2017","journal-title":"J. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical Presentation and Prognosis in MOG-Antibody Disease: A UK Study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"102399","DOI":"10.1016\/j.msard.2020.102399","article-title":"Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica","volume":"45","author":"Ciotti","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: A multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_48","first-page":"e1858","article-title":"Clinical Spectrum and Prognostic Value of CNS MOG Autoimmunity in Adults: The MOGADOR Study","volume":"90","author":"Ruiz","year":"2018","journal-title":"Neurology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and Related Disorders: A Multicenter Study of 50 Patients. Part 2: Epidemiology, Clinical Presentation, Radiological and Laboratory Features, Treatment Responses, and Long-Term Outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00415-013-6957-4","article-title":"Chronic Relapsing Inflammatory Optic Neuropathy: A Systematic Review of 122 Cases Reported","volume":"261","author":"Petzold","year":"2014","journal-title":"J. Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Netravathi, M., Venkappayya Holla, V., Nalini, A., Yadav, R., Vengalil, S., Oommen, A., Shaik Reshma, S., Kamble, N., Thomas, P., and Maya, B. (2020). Myelin oligodendrocyte glycoprotein-antibody-associated disorder: A new inflammatory CNS demyelinating disorder. J. Neurol.","DOI":"10.1007\/s00415-020-10300-z"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12974-016-0719-z","article-title":"MOG-IgG in NMO and Related Disorders: A Multicenter Study of 50 Patients. Part 3: Brainstem Involvement\u2014Frequency, Presentation and Outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"102057","DOI":"10.1016\/j.msard.2020.102057","article-title":"Seizure Occurrence in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Systematic Review and Meta-Analysis","volume":"42","author":"Shen","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1528-1167.2008.01565.x","article-title":"Seizures in Multiple Sclerosis","volume":"49","author":"Koch","year":"2008","journal-title":"Epilepsia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fneur.2020.00031","article-title":"A Fulminant Case of Demyelinating Encephalitis with Extensive Cortical Involvement Associated with Anti-MOG Antibodies","volume":"11","author":"Hochmeister","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic\u2019s syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1212\/01.CON.0000389937.69413.15","article-title":"Neuromyelitis spectrum disorders","volume":"16","author":"Wingerchuk","year":"2010","journal-title":"Contin. Lifelong Learn. Neurol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12974-020-01824-2","article-title":"In cooperation with the Neuromyelitis Optica Study Group (NEMOS). Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients","volume":"17","author":"Jarius","year":"2020","journal-title":"J. Neuroinflamm."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"Guo","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s00415-017-8615-8","article-title":"Optic Neuritis in Patients with Anti-MOG Antibodies Spectrum Disorder: MRI and Clinical Features from a Large Multicentric Cohort in France","volume":"264","author":"Biotti","year":"2017","journal-title":"J. Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological Differentiation of Optic Neuritis with Myelin Oligodendrocyte Glycoprotein Antibodies, Aquaporin-4 Antibodies, and Multiple Sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult. Scler."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, Radiologic, and Prognostic Features of Myelitis Associated with Myelin Oligodendrocyte Glycoprotein Autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00415-018-8781-3","article-title":"MRI of the First Event in Pediatric Acquired Demyelinating Syndromes with Antibodies to Myelin Oligodendrocyte Glycoprotein","volume":"265","author":"Baumann","year":"2018","journal-title":"J. Neurol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1007\/s00415-019-09440-8","article-title":"Unilateral Cortical FLAIR-Hyperintense Lesions in Anti-MOG-Associated Encephalitis with Seizures (FLAMES): Characterization of a Distinct Clinico-Radiographic Syndrome","volume":"266","author":"Budhram","year":"2019","journal-title":"J. Neurol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1212\/WNL.94.15_supplement.862","article-title":"Adding FUEL to the FLAMES: FLAIR-Variable Unilateral Enhancement of the Leptomeninges (FUEL) in MOG-IgG-Associated Disease","volume":"94","author":"Budhram","year":"2020","journal-title":"Neurology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/jnnp-2016-314005","article-title":"Brain Lesion Distribution Criteria Distinguish MS from AQP4-Antibody NMOSD and MOG-Antibody Disease","volume":"88","author":"Tackley","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1007\/s00330-019-06506-z","article-title":"Quantitative Brain Lesion Distribution May Distinguish MOG-Ab and AQP4-Ab Neuromyelitis Optica Spectrum Disorders","volume":"30","author":"Yang","year":"2020","journal-title":"Eur. Radiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1007\/s00415-018-9122-2","article-title":"Neurological update: MOG antibody disease","volume":"266","author":"Jacob","year":"2019","journal-title":"J. Neurol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1212\/NXI.0000000000000322","article-title":"MOG Antibody-Positive, Benign, Unilateral, Cerebral Cortical Encephalitis with Epilepsy","volume":"4","author":"Ogawa","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/ene.13790","article-title":"Encephalitis Is an Important Clinical Component of Myelin Oligodendrocyte Glycoprotein Antibody Associated Demyelination: A Single-Center Cohort Study in Shanghai, China","volume":"26","author":"Wang","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-019-1525-1","article-title":"Evaluation of Treatment Response in Adults with Relapsing MOG-Ab-Associated Disease","volume":"16","author":"Rollot","year":"2019","journal-title":"J. Neuroinflamm."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical Course, Therapeutic Responses and Outcomes in Relapsing MOG Antibody-Associated Demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease Course and Treatment Responses in Children with Relapsing Myelin Oligodendrocyte Glycoprotein Antibody\u2013Associated Disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e705","DOI":"10.1212\/NXI.0000000000000705","article-title":"Long-Term Efficacy of Mycophenolate Mofetil in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: A Prospective Study","volume":"7","author":"Li","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.25648","article-title":"Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases","volume":"87","author":"Durozard","year":"2020","journal-title":"Ann. Neurol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/WNF.0000000000000176","article-title":"Intravenous Immunoglobulin Therapy in a Patient with Anti-Myelin Oligodendrocyte Glycoprotein-Seropositive Neuromyelitis Optica","volume":"39","author":"Matarazzo","year":"2016","journal-title":"Clin. Neuropharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid Sparing Maintenance Immunotherapy for MOG-IgG Associated Disorder","volume":"95","author":"Chen","year":"2020","journal-title":"Neurology"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/1\/100\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:45:28Z","timestamp":1760179528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/1\/100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,24]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["ijms22010100"],"URL":"https:\/\/doi.org\/10.3390\/ijms22010100","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,24]]}}}